Soleno Therapeutics, Atossa Genetics, Agile Therapeutics, Syros Pharmaceuticals and Conatus Pharmaceuticals were last week’s top gainers.
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was in the green again last week, rising from 3,424.64 points on Monday to 3,581.09 points on Friday (March 15) as of 2:18 p.m. EST, representing a 4.56 percent increase.
On Thursday (March 14), Atossa Genetics (NASDAQ:ATOS) announced that the US Food and Drug Administration (FDA) gave the company expanded access program approval for its oral version of Endoxifen, which is for use as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient.
As a result of the approval, shares of Atossa Genetics roared over 368 percent over the trading period.
That being said, Atossa’s news didn’t land the company as the top gaining stock of the week despite still making the list. The five top gaining stocks of the week included:
- Soleno Therapeutics (NASDAQ:SLNO)
- Atossa Genetics
- Agile Therapeutics (NASDAQ:AGRX)
- Syros Pharmaceuticals (NASDAQ:SYRS)
- Conatus Pharmaceuticals (NASDAQ:CNAT)
Here’s a closer look at those companies and what may have moved their share prices.
First on the list is Soleno Therapeutics, which is a company focused on developing treatments for rare diseases. Soleno Therapeutics’ product candidate is Diazoxide Choline Controlled-Release, which is a controlled released one-a-day tablet and is a first line therapy to treat a range of rare diseases in neoanates, children and adults.
On Thursday, the company announced that the Data Safety Monitoring Board recommended the continuation of the company’s Phase III Trial in Prader-Wili Syndrome patients.,
Shares of the company jumped 169.87 percent over the five-day trading period to US$4.22 as of 2:48 p.m. EST on Friday.
Next on the list is Atossa Genetics, which is a company working to develop treatments for breast cancer and other breast conditions. Its drug, Endoxifen, is geared to mitigate breast cancer risk, reduce the cancer cell activity before surgery and reduce the risk of recurrent or new breast cancer after the initial treatment.
As mentioned above, the company received approval from the FDA to use the oral version of Endoxifen for use as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. The patient finished a three-week course of the drug before surgery during the FDA-approved expanded access program.
Shares of the company jumped 368 percent following the news to US$7.07 as of Thursday’s close. By Friday, Atossa’s stock had tumbled more 49.65 percent, although it is still up 138.66 percent over the week to US$3.63 as of 2:54 p.m. EST on Friday.
Middle of the pack is Agile Therapeutics, a company which is developing products to provide women with contraceptive options. Agile’s lead product is Twirla, which is a once a week prescription contraceptive patch.
The company released its Q4 and full year 2018 financial results on Tuesday (March 12), and provided an update on Twirla. According to the release, the FDA denied Agile’s formal dispute resolution appeal and instead provided an alternative method for resubmitting the new drug application.
The FDA recommended that the company conduct a “comparative wear study” to see whether or not Twirla demonstrates a “generally similar adhesion performance to Xulane.”
Shares of Agile rose 36.98 percent last week to US$1.56 as of 2:59 p.m. EST on Friday.
Next is Syros Pharmaceuticals, which has platform dedicated to analyzing the non-coding regulatory region of the genome. The company is currently focused on cancer and monogenic diseases and has a growing pipeline of gene control medicines.
Syros’ lead drug candidates include SY-1424, which is a in a Phase 2 clinical trial tor genomically defined subsets of patients with acute myeloid leukemia, and SY-1365, which is in a Phase 1 clinical trial for patients with ovarian and breast cancer.
Shares of the company increased 36.80 percent last week to US$8.87 as of 3 p.m. EST on Friday despite not having any news last week.
Closing out the list is Conatus Pharmaceuticals, which is a company focused on developing treatments for liver disease. Its lead product is an orally active pan-caspase protease inhibitor which is to reduce activity of human caspases.
Its lead internally compound product is CTS-2090, which is geared towards treating patients with chronic diseases involving inflammasome pathways. The company is also developing its lead in-licensed compound, emericasan, to treat patients with NASh-driven chronic liver diseases.
The company announced on Wednesday (March 13) that it will be presenting at the EASL meeting to discuss results of its ENCORE-PH Phase 2b clinical trial in patients with NASHCirrhosis and severe portal hypertension.
Shares of Conatus were up 36.55 percent to US$2.71 as of 3:13 p.m. EST on Friday.
NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EST using TradingView’s Stock Screener. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Don’t forget to follow us at @INN_LifeScience for real-time updates!
Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.